Symbols / IXHL $2.56 -11.72% Incannex Healthcare Inc.
IXHL Chart
About
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 35.77M |
| Enterprise Value | -34.10M | Income | -48.50M | Sales | — |
| Book/sh | 6.13 | Cash/sh | 5.77 | Dividend Yield | — |
| Payout | 0.00% | Employees | 12 | IPO | — |
| P/E | — | Forward P/E | -1.31 | PEG | — |
| P/S | inf | P/B | 0.42 | P/C | — |
| EV/EBITDA | 1.34 | EV/Sales | — | Quick Ratio | 47.96 |
| Current Ratio | 48.27 | Debt/Eq | 0.22 | LT Debt/Eq | — |
| EPS (ttm) | -22.20 | EPS next Y | -1.96 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-13 07:00 | ROA | -36.96% |
| ROE | -130.43% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 13.97M |
| Shs Float | 10.69M | Short Float | 9.15% | Short Ratio | 1.80 |
| Short Interest | — | 52W High | 49.80 | 52W Low | 2.40 |
| Beta | 2.73 | Avg Volume | 464.11K | Volume | 669.47K |
| Target Price | — | Recom | None | Prev Close | $2.90 |
| Price | $2.56 | Change | -11.72% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
- IXHL Stock Price, Quote & Chart | INCANNEX HEALTHCARE INC (NASDAQ:IXHL) - ChartMill hu, 02 Apr 2026 07
- IXHL SEC Filings - Incannex Healthcare Ltd 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 02
- IXHL Should I Buy - Intellectia AI Fri, 03 Apr 2026 07
- Incannex Healthcare Inc. (IXHL) Implements 1-for-30 Reverse Split Effective February 26 - finance.yahoo.com ue, 03 Mar 2026 08
- Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update - MarketBeat ue, 10 Mar 2026 07
- Why Did IXHL Stock Tank Over 32% Today? - Stocktwits Wed, 25 Feb 2026 14
- Incannex Healthcare Inc. Announces 1-for-30 Reverse Stock Split to Regain Nasdaq Compliance | IXHL Stock News - Quiver Quantitative Wed, 25 Feb 2026 08
- Market Movers | Winners: AGRZ, EONR, TLYS | Losers: IXHL, AIV, NOA - Trefis Fri, 13 Mar 2026 07
- Should I buy Incannex Healthcare Inc. (IXHL) - Zacks Investment Research Mon, 01 Dec 2025 08
- Sleep apnea pill from Incannex cut apnea events by up to 83% in trial - Stock Titan hu, 12 Mar 2026 07
- What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock - finance.yahoo.com Mon, 01 Dec 2025 08
- Two trading days in, Incannex revives stock buybacks with $18.5M left - Stock Titan Fri, 27 Mar 2026 07
- Biotech Incannex clears Nasdaq listing hurdle, holds $75M cash and no debt - Stock Titan ue, 17 Mar 2026 07
- Incannex Healthcare (NASDAQ: IXHL) restarts share buyback, holding $75M cash and no debt - Stock Titan Fri, 27 Mar 2026 07
- Inside the expert panel steering Incannex’s next PSX-001 trials - Stock Titan hu, 29 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.01
|
0.00
|
0.00
-100.00%
|
1.43
|
| Operating Revenue |
|
0.01
|
0.00
|
0.00
-100.00%
|
1.43
|
| Cost Of Revenue |
|
—
|
0.00
-100.00%
|
0.00
-99.36%
|
0.69
|
| Reconciled Cost Of Revenue |
|
—
|
0.00
-100.00%
|
0.00
-99.36%
|
0.69
|
| Gross Profit |
|
—
|
0.00
+100.00%
|
-0.00
-100.59%
|
0.74
|
| Operating Expense |
|
18.62
+36.52%
|
13.64
+34.23%
|
10.16
+9.08%
|
9.31
|
| Research And Development |
|
12.88
+104.14%
|
6.31
+70.73%
|
3.70
+3.55%
|
3.57
|
| Selling General And Administration |
|
17.07
+115.43%
|
7.92
+13.16%
|
7.00
+21.29%
|
5.77
|
| Selling And Marketing Expense |
|
1.05
-15.53%
|
1.25
-33.89%
|
1.89
-42.14%
|
3.27
|
| General And Administrative Expense |
|
16.02
+139.94%
|
6.67
+30.53%
|
5.11
+103.85%
|
2.51
|
| Salaries And Wages |
|
11.74
+160.76%
|
4.50
+87.98%
|
2.39
+68.03%
|
1.42
|
| Other Gand A |
|
3.93
+88.09%
|
2.09
-20.89%
|
2.64
+165.11%
|
1.00
|
| Other Operating Expenses |
|
-11.43
-1574.08%
|
-0.68
|
—
|
-0.03
|
| Total Expenses |
|
18.62
+36.52%
|
13.64
+34.18%
|
10.16
+1.65%
|
10.00
|
| Operating Income |
|
-18.61
-36.43%
|
-13.64
-34.18%
|
-10.16
-18.55%
|
-8.57
|
| Total Operating Income As Reported |
|
-30.04
+39.52%
|
-49.67
|
—
|
—
|
| EBITDA |
|
-18.33
-35.25%
|
-13.55
-33.31%
|
-10.16
-18.55%
|
-8.57
|
| Normalized EBITDA |
|
-18.30
-183.69%
|
21.86
+317.09%
|
-10.07
|
—
|
| Reconciled Depreciation |
|
0.10
+17.05%
|
0.09
|
0.00
|
0.00
|
| EBIT |
|
-18.43
-35.13%
|
-13.64
-34.18%
|
-10.16
-18.55%
|
-8.57
|
| Total Unusual Items |
|
-0.03
+99.92%
|
-35.41
-38139.73%
|
-0.09
|
—
|
| Total Unusual Items Excluding Goodwill |
|
-0.03
+99.92%
|
-35.41
-38139.73%
|
-0.09
|
—
|
| Special Income Charges |
|
0.00
+100.00%
|
-35.35
-38067.39%
|
-0.09
|
0.00
|
| Other Special Charges |
|
—
|
35.35
|
—
|
—
|
| Write Off |
|
—
|
0.00
-100.00%
|
0.09
|
0.00
|
| Net Income |
|
-18.46
+62.18%
|
-48.81
-376.09%
|
-10.25
-19.99%
|
-8.54
|
| Pretax Income |
|
-18.43
+62.24%
|
-48.81
-376.09%
|
-10.25
-19.99%
|
-8.54
|
| Net Non Operating Interest Income Expense |
|
0.21
-14.52%
|
0.24
+5486.62%
|
0.00
+114.32%
|
0.00
|
| Net Interest Income |
|
0.21
-14.52%
|
0.24
+5486.62%
|
0.00
+114.32%
|
0.00
|
| Interest Income Non Operating |
|
0.21
-14.52%
|
0.24
+5486.62%
|
0.00
+114.32%
|
0.00
|
| Interest Income |
|
0.21
-14.52%
|
0.24
+5486.62%
|
0.00
+114.32%
|
0.00
|
| Other Income Expense |
|
-0.03
+99.92%
|
-35.41
-38139.73%
|
-0.09
-446.54%
|
0.03
|
| Other Non Operating Income Expenses |
|
—
|
1.38
+74.56%
|
0.79
+2851.07%
|
0.03
|
| Gain On Sale Of Security |
|
-0.03
+58.21%
|
-0.07
|
—
|
—
|
| Tax Provision |
|
0.03
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.01
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-18.46
+62.18%
|
-48.81
-376.09%
|
-10.25
-19.99%
|
-8.54
|
| Net Income From Continuing Operation Net Minority Interest |
|
-18.46
+62.18%
|
-48.81
-376.09%
|
-10.25
-19.99%
|
-8.54
|
| Net Income From Continuing And Discontinued Operation |
|
-18.46
+62.18%
|
-48.81
-376.09%
|
-10.25
-19.99%
|
-8.54
|
| Net Income Continuous Operations |
|
-18.46
+62.18%
|
-48.81
-376.09%
|
-10.25
-19.99%
|
-8.54
|
| Normalized Income |
|
-18.44
-37.64%
|
-13.40
-31.86%
|
-10.16
|
—
|
| Net Income Common Stockholders |
|
-18.46
+62.18%
|
-48.81
-376.09%
|
-10.25
-19.99%
|
-8.54
|
| Diluted EPS |
|
-34.50
-3241.04%
|
-1.03
-0.07%
|
-1.03
|
—
|
| Basic EPS |
|
-34.50
-3241.04%
|
-1.03
-0.07%
|
-1.03
|
—
|
| Basic Average Shares |
|
0.54
-95.79%
|
12.81
+29.02%
|
9.93
|
—
|
| Diluted Average Shares |
|
0.54
-95.79%
|
12.81
+29.02%
|
9.93
|
—
|
| Diluted NI Availto Com Stockholders |
|
-18.46
+62.18%
|
-48.81
-376.09%
|
-10.25
-19.99%
|
-8.54
|
| Depreciation Amortization Depletion Income Statement |
|
0.10
+17.05%
|
0.09
|
0.00
|
—
|
| Depreciation And Amortization In Income Statement |
|
0.10
+17.05%
|
0.09
|
0.00
|
—
|
| Depreciation Income Statement |
|
0.10
+17.05%
|
0.09
|
0.00
|
—
|
| Other Taxes |
|
—
|
-0.67
-24.69%
|
-0.54
|
0.00
|
| Rent And Landing Fees |
|
0.35
+314.29%
|
0.08
+8.70%
|
0.08
-11.20%
|
0.09
|
| Rent Expense Supplemental |
|
0.35
+314.29%
|
0.08
+8.70%
|
0.08
-11.20%
|
0.09
|
| Line Item | Trend | 2023-06-30 | 2022-06-30 |
|---|---|---|---|
| Total Assets |
|
23.78
-8.73%
|
26.06
|
| Current Assets |
|
23.00
-11.75%
|
26.06
|
| Cash Cash Equivalents And Short Term Investments |
|
22.12
-14.25%
|
25.80
|
| Cash And Cash Equivalents |
|
22.12
-14.25%
|
25.80
|
| Cash Financial |
|
22.08
-14.39%
|
25.80
|
| Receivables |
|
0.19
-12.92%
|
0.22
|
| Accounts Receivable |
|
0.29
|
—
|
| Gross Accounts Receivable |
|
—
|
—
|
| Other Receivables |
|
—
|
—
|
| Taxes Receivable |
|
0.19
-5.79%
|
0.20
|
| Prepaid Assets |
|
0.69
+1566.60%
|
0.04
|
| Other Current Assets |
|
1.04
|
—
|
| Total Non Current Assets |
|
0.79
|
0.00
|
| Net PPE |
|
0.79
|
0.00
|
| Gross PPE |
|
0.81
|
0.00
|
| Accumulated Depreciation |
|
-0.02
|
—
|
| Properties |
|
0.00
|
—
|
| Buildings And Improvements |
|
0.49
|
—
|
| Machinery Furniture Equipment |
|
0.16
|
—
|
| Construction In Progress |
|
0.16
|
—
|
| Other Properties |
|
1.19
|
—
|
| Goodwill And Other Intangible Assets |
|
34.90
|
0.00
|
| Total Liabilities Net Minority Interest |
|
2.96
+113.87%
|
1.38
|
| Current Liabilities |
|
2.55
+84.37%
|
1.38
|
| Payables And Accrued Expenses |
|
2.17
+84.15%
|
1.18
|
| Payables |
|
1.75
+95.36%
|
0.89
|
| Accounts Payable |
|
1.75
+95.36%
|
0.89
|
| Other Payable |
|
—
|
—
|
| Current Accrued Expenses |
|
0.43
+49.06%
|
0.29
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.26
+29.87%
|
0.20
|
| Current Debt And Capital Lease Obligation |
|
0.11
|
—
|
| Current Capital Lease Obligation |
|
0.11
|
0.00
|
| Current Deferred Liabilities |
|
0.00
|
—
|
| Current Deferred Revenue |
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.41
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.41
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.41
|
0.00
|
| Stockholders Equity |
|
20.82
-15.60%
|
24.67
|
| Common Stock Equity |
|
20.82
-15.60%
|
24.67
|
| Capital Stock |
|
0.00
-100.00%
|
59.56
|
| Common Stock |
|
0.00
-100.00%
|
59.56
|
| Preferred Stock |
|
0.00
|
—
|
| Share Issued |
|
0.53
+22.80%
|
0.43
|
| Ordinary Shares Number |
|
0.53
+22.80%
|
0.43
|
| Treasury Shares Number |
|
0.00
|
0.00
|
| Additional Paid In Capital |
|
116.29
|
—
|
| Retained Earnings |
|
-92.21
-127.99%
|
-40.45
|
| Gains Losses Not Affecting Retained Earnings |
|
-3.25
|
—
|
| Other Equity Adjustments |
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
20.82
-15.60%
|
24.67
|
| Total Capitalization |
|
20.82
-15.60%
|
24.67
|
| Working Capital |
|
20.45
-17.13%
|
24.67
|
| Invested Capital |
|
20.82
-15.60%
|
24.67
|
| Total Debt |
|
0.52
|
0.00
|
| Capital Lease Obligations |
|
0.52
|
0.00
|
| Net Tangible Assets |
|
20.82
-15.60%
|
24.67
|
| Tangible Book Value |
|
20.82
-15.60%
|
24.67
|
| Foreign Currency Translation Adjustments |
|
-3.25
|
—
|
| Notes Receivable |
|
0.07
+298.91%
|
0.02
|
| Other Equity Interest |
|
7.98
+43.68%
|
5.56
|
| Line Item | Trend | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-15.85
-47.41%
|
-10.75
-22.00%
|
-8.81
-69.70%
|
-5.19
|
| Cash Flow From Continuing Operating Activities |
|
-15.85
-47.41%
|
-10.75
-22.00%
|
-8.81
-69.70%
|
-5.19
|
| Net Income From Continuing Operations |
|
-18.46
+62.18%
|
-48.81
-376.09%
|
-10.25
-19.99%
|
-8.54
|
| Depreciation Amortization Depletion |
|
0.10
+17.05%
|
0.09
|
0.00
|
0.00
|
| Depreciation And Amortization |
|
0.10
+17.05%
|
0.09
|
0.00
|
0.00
|
| Other Non Cash Items |
|
—
|
-0.00
+98.96%
|
-0.41
-114.05%
|
2.91
|
| Stock Based Compensation |
|
8.93
+315.45%
|
2.15
+113.30%
|
1.01
+123.47%
|
0.45
|
| Provisionand Write Offof Assets |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Operating Gains Losses |
|
0.03
|
—
|
—
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
0.03
|
0.00
|
—
|
—
|
| Change In Working Capital |
|
-6.45
-117.99%
|
35.83
+4146.49%
|
0.84
+19387.13%
|
0.00
|
| Change In Receivables |
|
-9.84
|
0.00
+100.00%
|
-0.06
-139.33%
|
0.16
|
| Change In Inventory |
|
—
|
—
|
0.00
-100.00%
|
0.14
|
| Change In Prepaid Assets |
|
0.37
+158.95%
|
-0.63
|
—
|
—
|
| Change In Payables And Accrued Expense |
|
3.02
+173.82%
|
1.10
+44.44%
|
0.76
+449.21%
|
-0.22
|
| Change In Payable |
|
3.02
+173.82%
|
1.10
|
—
|
—
|
| Change In Other Current Assets |
|
0.00
-100.00%
|
35.35
+96038.66%
|
0.04
+28350.58%
|
0.00
|
| Change In Other Current Liabilities |
|
—
|
0.07
-35.57%
|
0.11
+239.54%
|
-0.08
|
| Investing Cash Flow |
|
-0.28
+12.34%
|
-0.32
|
0.00
-100.00%
|
0.02
|
| Cash Flow From Continuing Investing Activities |
|
-0.28
+12.34%
|
-0.32
|
0.00
-100.00%
|
0.02
|
| Net PPE Purchase And Sale |
|
-0.28
+12.34%
|
-0.32
|
0.00
|
0.00
|
| Purchase Of PPE |
|
-0.28
+12.34%
|
-0.32
|
0.00
|
—
|
| Sale Of PPE |
|
—
|
—
|
0.00
|
0.00
|
| Capital Expenditure |
|
-0.28
+12.34%
|
-0.32
|
—
|
—
|
| Net Business Purchase And Sale |
|
—
|
—
|
0.00
-100.00%
|
0.02
|
| Financing Cash Flow |
|
0.00
-100.00%
|
8.18
-71.15%
|
28.33
+204.08%
|
9.32
|
| Cash Flow From Continuing Financing Activities |
|
0.00
-100.00%
|
8.18
-71.15%
|
28.33
+204.08%
|
9.32
|
| Net Issuance Payments Of Debt |
|
—
|
-0.04
|
0.00
|
—
|
| Repayment Of Debt |
|
—
|
-0.04
|
0.00
|
—
|
| Long Term Debt Payments |
|
—
|
-0.04
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
—
|
-0.04
|
0.00
|
—
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
8.18
-71.15%
|
28.33
+204.08%
|
9.32
|
| Changes In Cash |
|
-16.12
-457.85%
|
-2.89
-114.80%
|
19.52
+370.66%
|
4.15
|
| Effect Of Exchange Rate Changes |
|
-0.14
+83.01%
|
-0.82
|
0.00
|
0.00
|
| Beginning Cash Position |
|
22.12
-14.38%
|
25.83
+311.62%
|
6.28
+131.82%
|
2.71
|
| End Cash Position |
|
5.86
-73.52%
|
22.12
-14.25%
|
25.80
+276.33%
|
6.85
|
| Free Cash Flow |
|
-16.12
-45.70%
|
-11.06
-25.59%
|
-8.81
-69.70%
|
-5.19
|
| Cash Flowsfromusedin Operating Activities Direct |
|
—
|
-15.94
-24.48%
|
-12.81
-146.68%
|
-5.19
|
| Classesof Cash Payments |
|
—
|
-17.29
-27.14%
|
-13.60
-100.76%
|
-6.77
|
| Classesof Cash Receiptsfrom Operating Activities |
|
—
|
1.01
+29.59%
|
0.78
-48.10%
|
1.51
|
| Common Stock Issuance |
|
0.00
-100.00%
|
8.18
-71.15%
|
28.33
+204.08%
|
9.32
|
| Interest Received Direct |
|
—
|
0.33
+5148.88%
|
0.01
-91.42%
|
0.07
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
8.18
-71.15%
|
28.33
+204.08%
|
9.32
|
| Other Cash Paymentsfrom Operating Activities |
|
—
|
-17.29
|
—
|
—
|
| Other Cash Receiptsfrom Operating Activities |
|
—
|
1.01
+29.59%
|
0.78
+844.83%
|
0.08
|
| Paymentson Behalfof Employees |
|
—
|
—
|
-13.60
-51.58%
|
-8.97
|
| Paymentsto Suppliersfor Goodsand Services |
|
—
|
—
|
—
|
-6.77
|
| Receiptsfrom Customers |
|
—
|
0.00
|
0.00
-100.00%
|
1.51
|
| Sale Of Business |
|
—
|
—
|
0.00
-100.00%
|
0.02
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-27 View
- 8-K2026-03-25 View
- 8-K2026-03-18 View
- 8-K2026-03-17 View
- 8-K2026-03-12 View
- 8-K2026-03-12 View
- 8-K2026-02-25 View
- 10-Q2026-02-13 View
- 8-K2026-01-29 View
- 8-K2026-01-22 View
- 8-K2026-01-16 View
- 8-K2026-01-15 View
- 8-K2026-01-14 View
- 8-K2025-12-18 View
- 8-K2025-12-03 View
- 10-Q2025-11-14 View
- 42025-11-14 View
- 42025-11-14 View
- 42025-11-14 View
- 42025-11-14 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|